Compare RGTI & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGTI | ABVX |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 9.0B |
| IPO Year | N/A | N/A |
| Metric | RGTI | ABVX |
|---|---|---|
| Price | $22.02 | $133.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $29.38 | ★ $115.83 |
| AVG Volume (30 Days) | ★ 36.5M | 1.8M |
| Earning Date | 11-10-2025 | 08-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,494,000.00 | $6,231,374.00 |
| Revenue This Year | N/A | $6.80 |
| Revenue Next Year | $167.54 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.95 | $4.77 |
| 52 Week High | $58.15 | $148.83 |
| Indicator | RGTI | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 38.74 | 57.38 |
| Support Level | $21.53 | $139.42 |
| Resistance Level | $22.96 | $147.00 |
| Average True Range (ATR) | 1.77 | 7.25 |
| MACD | -0.03 | 0.98 |
| Stochastic Oscillator | 7.74 | 63.38 |
Rigetti Computing Inc is engaged in the business of full-stack quantum computing. The company offers full-stack quantum computing platform as a cloud service to a wide range of end-users, directly through its Rigetti QCS platform, and also through cloud service providers. Its proprietary quantum-classical infrastructure provides ultra-low latency integration with public and private clouds for high-performance practical quantum computing. The company has developed the industry's first multi-chip quantum processor for scalable quantum computing systems. Geographically, the company derives the majority of its revenue from the United States.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.